Xolair 300 MG/2 ML autoinject 2ML
Ended Awarded
- Contract number
- SPE2DB25FN3QY
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $3,188
Award facts
- Contract value 100% obligated
- $3,188.32 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Xolair (omalizumab) 300 mg/2 mL auto-injector vials valued at $3,188.32 under a firm fixed-price contract. The delivery order, issued on August 6, 2025, with a completion date of August 27, 2025, represents a non-competitively set-aside procurement. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will fulfill this order from its corporate office location. This delivery order is a child contract issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated as SPE2DX and valued at $999,999,999.00 through December 2026.
Xolair is a biologic medication used primarily for moderate-to-severe allergic asthma and chronic idiopathic urticaria. As a critical pharmaceutical distributor for the Defense Logistics Agency's Medical Supply Chain, AmerisourceBergen Drug Corp supports military and veteran healthcare systems through a comprehensive portfolio of brand-name and generic medications, vaccines, and specialized medical supplies. The SPE2DX vehicle enables the company to supply pharmaceutical products and medical commodities globally to support Defense Health Agency programs and other federal healthcare systems, with the Defense Logistics Agency planning to establish additional regional pharmaceutical prime vendor contracts under the upcoming Generation V program structure.
Quick answers
Who was awarded contract SPE2DB25FN3QY?
SPE2DB25FN3QY was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on August 6, 2025.
How much is contract SPE2DB25FN3QY worth?
The government has obligated $3,188 on SPE2DB25FN3QY.
Is contract SPE2DB25FN3QY an order under another contract?
Yes. SPE2DB25FN3QY is a delivery order under SPE2DB22D1200, an indefinite delivery contract.
Was contract SPE2DB25FN3QY competed?
The extent of competition for SPE2DB25FN3QY was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award